Share this PR

Press Contact

kdm communications

kdm communications

1480405333

Contact Email

Social Media

Dolomite Bio introduces the Nadia product family for single cell research

PressReleasePing - November 09, 2017 -Dolomite Bio is delighted to announce the launch of the game-changing Nadia single cell platform, a groundbreaking system set to escalate scRNA-Seq to new heights, offering the fast-growing single cell research sector an innovative solution for a wide range of potential applications. This novel product family will be on display from the 9th to the 10th of November 2017 at the 5th Annual Single Cell Analysis Congress (Booth 14) in London, UK, at Oz Single Cells 2017 in Melbourne, Australia, and at the 3rd Annual Boston Understand Your Genome® (UYG) Conference in Cambridge, USA, on the 14th of the month. The Nadia instrument is a touchscreen-controlled, droplet-based microfluidic platform for single cell research, combining superior microfluidics, automated temperature control and gentle cell/bead agitation to offer a single compact instrument that delivers highly precise and reliable results. One, two, four or eight samples can be run in parallel, generating up to 6,000 high quality, single cell libraries per sample in approximately 15 minutes. Configuration with the Nadia Innovate protocol development platform transforms the system into a scalable, open system for the creation of new procedures and applications. Users can alter parameters – such as droplet size and frequency, temperature, agitation and timings – and optimize protocols with the aid of real-time visualization, enabling straightforward development of new single cell protocols and applications. Mike Hawes, CEO of Dolomite Bio, commented: “We are excited to be launching the Nadia product family at conferences across three continents. This novel system represents a huge leap forward for single cell research, and we look forward to showcasing its capabilities.” For more information, visit www.dolomite-bio.com/product/nadia-instrument/


Creative Commons License

This press release is licensed under a Creative Commons Attribution 3.0 Unported License.